Medexus Pharmaceuticals Inc has seen slight fluctuations this week, reflecting ongoing developments in its product performance.
Medexus Pharmaceuticals Inc (MDP.TO) has experienced a modest price change this week, with a slight increase of 0.20%. Despite some recent volatility, the company's stock remains significantly up for the year, reflecting overall positive market sentiment around its product offerings.
Investor takeaway: Investors should monitor Medexus' upcoming performance and product developments, especially following its recent fiscal Q1 results, which indicated strong product-level performance for GRAFAPEX.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.33M
52W high
$5.50
52W low
$2.51
1W change
+0.20%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP · as of Sep 17, 2026
Wall Street analysts forecast MDP stock price to rise 43.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+43.8% Upside
Current Price
C$5.04
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
24.0%
Annualized
90-Day Vol
37.9%
Annualized
Trend (90d)
+48.5%
Annualized drift
90d Mean
C$5.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.34 | C$4.92 – C$5.80 |
| 60 trading days | C$5.66 | C$5.03 – C$6.36 |
| 90 trading days | C$5.99 | C$5.19 – C$6.92 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$5.04 Close with 63.11% Year-to-Date Gain
Medexus Pharmaceuticals has shown a notable year-to-date performance increase of 63.11%, indicating strong investor interest despite some recent fluctuations.
Bull case
The company's recent fiscal Q1 results highlighted the strongest performance for GRAFAPEX to date, suggesting a potential upward trend in sales and market acceptance.
Bear case
Even with positive quarterly results, Medexus still reports a negative profit margin and low returns on equity, which pose risks for investors.
Price Action Overview
Advertisement
Medexus Pharmaceuticals Inc closed at C$5.04 on Friday, reflecting a decrease of 0.59% for the day. Over the past week, the stock has slightly increased by 0.20%, while it has seen a decline of 2.14% over the past month. Year-to-date, the stock has shown a remarkable increase of 63.11%, indicating strong investor confidence in the company's growth potential.
Recent Company News
There have been no major news announcements this week impacting Medexus Pharmaceuticals. However, the company recently reported its fiscal Q1 2027 results, showcasing the strongest quarter of product-level performance for GRAFAPEX to date. This aligns with the company's ongoing focus on enhancing its product offerings and market presence.
Technical Picture
From a technical perspective, Medexus Pharmaceuticals is trading near its 50-day moving average of C$5.09, which is 1.0% lower than the current price. The stock has a 200-day moving average of C$3.88, indicating a significant 30.0% increase compared to its current trading price. The 52-week range for the stock has been between C$2.51 and C$5.50, with the current price sitting at approximately 85% of this range. The stock has a beta of 1.83, suggesting higher volatility compared to the market, and its recent volume of 24,826 shares is below the 20-day average of 33,638 shares, indicating reduced trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
